Home › Genocea Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy
 

Keywords :   


Genocea Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy

2014-07-30 09:52:30| drugdiscoveryonline Home Page

Genocea Biosciences, Inc. a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, recently announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2)

Tags: trial phase dose optimization

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Is China's bubble tea bubble about to burst?
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Business locked in expensive AI 'arms race'
17.05Is the move to electric cars running out of power?
17.05Pornhub partners with UK child abuse fighting charity
16.05CFTC charges Agridime and its co-founders with a fraudulent cattle scheme
16.05Baleage: Advantageous for first cutting hay
More »